New York greenlights a groundbreaking clinical trial of a THC-based oral solution, VER-01, targeting chronic sciatica pain—a move with national medical cannabis implications.

The FDA outlines its ibogaine trial vision, Compass Pathways reveals pricing and slow rollout plans, and early healthcare leaders weigh in—here’s what DMV readers need to know.

High Times reports a small clinical trial of an experimental medication for cannabis withdrawal. Here’s what we know now, how it could work, and what DMV patients should watch.

The FDA opened a 45‑day comment window on how to safely study ibogaine, seeking input on dosing, cardiac monitoring, ethics, and trial design—without touching legalization debates.

Oregon pauses a proposed psilocybin fee increase, California earmarks $4.7M for psychedelic research, and the DEA moves to schedule five tryptamines—here’s why it matters.

A landmark Phase 2 study will test smoked, high-THC flower versus placebo in 320 veteran participants with moderate to severe PTSD. Here’s what’s being studied and why it matters for DMV patients.

Psychedelic Alpha flagged a busy “Psychedelics Week” in DC with multiple meetings. Here’s what that activity could signal for policy, access, and the DMV community.

Psychedelic Alpha has introduced The Psychedelic News Feed Podcast, creating a new way to follow psychedelics developments. Here’s why DMV readers should care.

As 5‑MeO‑DMT draws buzz, scientists and conservationists warn against “toad milking.” Here’s what’s known, what’s not, and how DMV readers should approach it.

What a new psilocybin trial update means for evidence standards in medical cannabis and patient care, plus why rigorous methods matter for DMV patients.

A plain‑English guide to where psychedelic-assisted therapy is actually available now, how Oregon, Colorado and New Mexico differ, and what DC, Maryland and Virginia residents should know before making plans.

A Johns Hopkins pilot shows oral THC can feel psychedelic in controlled settings, reshaping dosing guidance, trial design, and how DMV consumers approach high-THC edibles.

A federal health R&D push is exploring ibogaine for opioid use disorder. Here’s what the ARPA-H workshop and ASCENT-IBO call mean for patients and the DMV.

Journalist Erica Rex urges caution: psychedelic states can open trauma and power imbalances. Here’s what ethical care, safety, and patient-centered practices should look like in the DMV.

A new federal push to speed psychedelic therapies highlights ibogaine and VA trials, but funding cuts, workforce gaps, and ethics could slow real-world access.

Exploring the science behind messianic experiences on psychedelics, clinical findings, and safe integration for DMV wellness seekers.

New York's amended Medical Psilocybin Act outlines clinical access rules, offering a therapeutic model for the East Coast and DMV region.

DoubleBlind Mag spotlights rising 'pill shaming' in psychedelic spaces. Here’s what it means for people on SSRIs, the early research, and how DMV readers can stay safe.

New preclinical data suggests whole-mushroom extracts may drive stronger, longer neuroplastic effects than lab-made psilocybin alone—echoing cannabis’s entourage effect.

What a World Cup controversy reveals about psychedelics, patents, and power—and why DMV patients should watch how culture gets packaged into products and protocols.